Avantor, Inc. (AVTR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Avantor, Inc. (AVTR) Healthcare & Pipeline Overview

Avantor, Inc. delivers essential products and services to diverse sectors including biopharma, healthcare, and advanced technologies. With a broad portfolio of materials, equipment, and specialty services, Avantor supports critical research and production processes across the Americas, Europe, Asia, and Africa, maintaining a significant presence in the medical instruments and supplies market.

What Is the Investment Thesis for AVTR?

The company’s comprehensive product and service portfolio, ranging from materials and consumables to equipment and specialty services, provides resilience against economic cycles. While the company currently has a negative profit margin of -8.4%, growth catalysts include expanding its service offerings and penetrating emerging markets. The company's beta of 1.00 indicates market correlation. Key value drivers include strategic acquisitions, operational efficiencies, and increasing demand for biopharmaceutical materials. However, investors should be aware of risks such as intense competition and potential fluctuations in demand from key customer segments.

Based on FMP financials and quantitative analysis

AVTR Key Highlights

Avantor serves a diverse range of industries including biopharma, healthcare, education and government, advanced technologies, and applied materials.

• The company offers a broad portfolio of materials and consumables, equipment and instrumentation, and services and specialty procurements.
• Avantor has a global presence, serving customers in the Americas, Europe, Asia, the Middle East, and Africa.
• The company's gross margin is 32.1%.
• Avantor employs approximately 13,500 people.

Who Are AVTR's Competitors?

AVTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AVTR's Key Strengths?

Diversified product and service portfolio.

• Global presence and established distribution network.
• Strong relationships with key customers in diverse industries.
• Expertise in providing mission-critical products and services.

What Are AVTR's Weaknesses?

Negative profit margin.

• Exposure to economic cycles and fluctuations in demand.
• Dependence on key suppliers for certain materials and components.
• Potential for product liability claims.

What Could Drive AVTR Stock Higher?

Expansion of service offerings in the biopharma sector to drive revenue growth.

• Penetration of emerging markets in Asia and Africa to diversify revenue streams.
• Potential strategic acquisitions to expand product portfolio and geographic reach.
• Increasing adoption of single-use technologies in biopharmaceutical manufacturing.
• Enhancement of digital capabilities to improve customer experience and operational efficiency.

What Are the Key Risks for AVTR?

Negative return on equity (-9.6%) — the business is not currently generating profit on shareholder capital.

• Intense competition from established players in the medical instruments and supplies industry.
• Stringent regulatory requirements and compliance costs impacting profitability.
• Disruptions in the supply chain affecting the availability of key materials and components.
• Technological advancements rendering existing products obsolete.
• Fluctuations in demand from key customer segments due to economic cycles.

What Are the Growth Opportunities for AVTR?

• Expansion of Biopharma Services: Avantor can capitalize on the growing biopharmaceutical market by expanding its service offerings, including biopharmaceutical material scale-up and development services. The global biopharmaceutical market is expected to reach $526 billion by 2028, presenting a significant opportunity for Avantor to increase its market share through specialized services and customized solutions. This expansion can be achieved through strategic partnerships and investments in advanced technologies.
• Penetration of Emerging Markets: Entering and expanding in emerging markets, particularly in Asia and Africa, offers substantial growth potential. These regions are experiencing rapid growth in healthcare spending and industrial development, creating a demand for Avantor's products and services. By establishing a stronger presence in these markets, Avantor can diversify its revenue streams and reduce its reliance on mature markets. This strategy involves building local partnerships and tailoring product offerings to meet regional needs.
• Strategic Acquisitions: Avantor can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Avantor's growth and enhance its competitive position. For example, acquiring a company specializing in advanced filtration systems could strengthen Avantor's equipment and instrumentation offerings. These acquisitions should be carefully evaluated to ensure they align with Avantor's overall strategy and create synergies.
• Focus on Single-Use Technologies: The increasing adoption of single-use technologies in biopharmaceutical manufacturing presents a significant growth opportunity for Avantor. Single-use systems offer advantages such as reduced cleaning requirements, lower capital investment, and faster changeover times. By investing in the development and manufacturing of customized single-use assemblies, Avantor can cater to the growing demand for these technologies and strengthen its relationships with biopharmaceutical customers. This includes expanding its offerings of single-use bioreactors, mixers, and fluid transfer systems.
• Enhancement of Digital Capabilities: Investing in digital technologies to improve customer experience and operational efficiency is crucial for sustained growth. This includes developing e-commerce platforms, implementing advanced data analytics, and leveraging artificial intelligence to optimize supply chain management. By enhancing its digital capabilities, Avantor can improve customer satisfaction, reduce costs, and gain a competitive edge in the market. This also involves providing customers with online tools for product selection, ordering, and technical support.

What Are AVTR's Competitive Advantages?

• Diversified product and service portfolio reduces reliance on any single product or market.
• Strong relationships with key customers in diverse industries provide recurring revenue.
• Global presence allows for economies of scale and access to multiple markets.
• Specialized expertise in providing mission-critical products and services creates a barrier to entry.
• Long-standing history and established reputation build trust and customer loyalty.

What Does AVTR Do?

Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor, Inc. has evolved into a global provider of mission-critical products and services. The company serves a wide array of industries, including biopharma, healthcare, education and government, advanced technologies, and applied materials. Avantor's offerings span materials and consumables, such as high-purity chemicals, reagents, lab supplies, formulated silicone materials, customized excipients, and single-use assemblies. They also provide process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. In addition to materials, Avantor supplies equipment and instrumentation, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and peristaltic pumps. The company further extends its capabilities through services and specialty procurements, offering onsite lab and production support, equipment services, procurement and sourcing solutions, and biopharmaceutical material scale-up and development services. Avantor also provides scientific research support services, including DNA extraction, bioreactor servicing, clinical and biorepository services, compound management, cleanroom control, monitoring, maintenance, and sanitization services. Avantor’s global presence allows it to serve customers across the Americas, Europe, Asia, the Middle East, and Africa, making it a key player in supporting scientific advancements and industrial processes worldwide. With a workforce of 13,500 employees, Avantor continues to innovate and expand its offerings to meet the evolving needs of its diverse customer base.

What Products and Services Does AVTR Offer?

• Provides materials and consumables like high-purity chemicals and reagents.
• Offers lab products and supplies, including customized excipients and single-use assemblies.
• Supplies equipment and instrumentation, such as filtration systems and incubators.
• Delivers services and specialty procurements, including onsite lab and production support.
• Provides scientific research support services like DNA extraction and bioreactor servicing.
• Serves the biopharma, healthcare, education, government, advanced technologies, and applied materials industries.
• Offers clinical trial kits and fluid handling tips.

How Does AVTR Make Money?

• Sells materials and consumables to research and production facilities.
• Provides equipment and instrumentation for laboratories and manufacturing processes.
• Offers services and specialty procurements, generating revenue through service contracts.
• Serves diverse industries, creating multiple revenue streams.
• Focuses on long-term relationships with customers, ensuring recurring revenue.

What Industry Does AVTR Operate In?

Avantor, Inc. operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2028, driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. Avantor competes with companies like Baxter International Inc. and Henry Schein, Inc., focusing on providing specialized products and services to maintain a competitive edge. The industry is also influenced by stringent regulatory requirements and the need for continuous product development to meet evolving customer needs.

Who Are AVTR's Key Customers?

• Biopharmaceutical companies conducting research and manufacturing.
• Healthcare providers and research institutions.
• Educational and governmental organizations.
• Advanced technology companies requiring specialized materials.
• Applied materials industries needing high-purity chemicals and equipment.

Over the past six months, Avantor, Inc. insiders filed 18 SEC Form 4 transactions — 5 sales and 13 purchases. On net that is roughly 626K shares acquired (about $2.0M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Avantor, Inc.

Revenue for Avantor, Inc. came in at $1.69B during Jun 2026, a 7.0% improvement versus the preceding quarter. The company recorded net income of $38.1M, with diluted EPS of $0.06. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, AVTR averaged $-0.21 in diluted EPS.

AVTR Valuation & Market Position

With a $10.1B market cap, Avantor, Inc. sits in the large-cap segment of the market. Analyst price targets span from $7.00 to $16.00, with a consensus of $11.67. At the current price of $14.88, that implies roughly 22% downside from the consensus target. Relative to its peer group, AVTR's quantitative score of 55/100 is roughly in line with the peer average of 62/100.

Return on equity for Avantor, Inc. stands at -9.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.4%, the inverse of the P/E and a quick read on earnings relative to price.

Avantor, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.81 places it in the grey zone, a middle ground that warrants monitoring.

Avantor, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.3% above estimates on average.

Wall Street analysts project Avantor, Inc. revenue of about $6.59B for fiscal 2026, with EPS near $0.81. The estimate reflects 12 contributing analysts.

Company Profile

Avantor, Inc. operates in the Medical Instruments & Supplies industry within the Healthcare sector. It is headquartered in Radnor, United States.

AVTR Financials

AVTR Latest News

AVTR Analyst Consensus

AVTR MoonshotScore

Latest Avantor, Inc. Analysis

Avantor, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources